Form 4: Apogee Therapeutics CEO Michael Henderson Sells Shares Under 10b5-1 Trading Plan

Apogee Therapeutics CEO Michael Henderson sold shares of the company's common stock on October 2, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Michael Henderson, CEO of Apogee Therapeutics, sold shares of common stock on October 2, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on September 25, 2023.
• A total of 30,288 shares were sold at a weighted average price of $56.07, with prices ranging from $55.51 to $56.50.
• An additional 9,712 shares were sold at a weighted average price of $56.74, with prices ranging from $56.52 to $57.11.
• Following the transactions, Henderson directly owns 1,354,487 shares of Apogee Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock sales by an executive. It doesn't contain any information that would significantly sway sentiment positively or negatively.

Industry Context

Sales by company executives are a normal part of corporate governance. The fact that the sales were executed under a 10b5-1 plan suggests that the sales were pre-planned and not based on any inside information.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, potentially creating downward pressure on the stock price in the short term.

Key Dates